Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus paclitaxel
capivasertib plus paclitaxel
BEECH, 2019
  NCT01625286
RCTla/mBC - HR-positive - 1st line (L1)capivasertib plus paclitaxelplacebo plus paclitaxelpatients with ER-positive advanced breast cancer with or without a PIK3CA mutation receiving chemotherapy for the first time in the advanced setting54 / 56low
inconclusive
  • inconclusive 20 % decrease in progression or deaths (PFS) (PE)

la/mBC - HR positive - L1 - PIK3CA mutant breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1) la/mBC - HR positive - L1 - PIK3CA mutant

versus paclitaxel
ipatasertib plus paclitaxel
IPATunity130, 2022
  NCT03337724
RCTla/mBC - HR positive - L1 - PIK3CA mutantipatasertib plus paclitaxelplacebo plus paclitaxelPatients with HR-positive and HER2-negative PIK3CA/AKT1/PTEN-altered measurable advanced breast cancer146 / 76low
inconclusive
  • inconclusive 0 % increase in progression or deaths (PFS) (PE)